4.6 Review

Emerging Tim-3 functions in antimicrobial and tumor immunity

Journal

TRENDS IN IMMUNOLOGY
Volume 32, Issue 8, Pages 345-349

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.it.2011.05.003

Keywords

-

Categories

Funding

  1. NIAID NIH HHS [P01 AI056299-07, P01 AI039671-15, P01 AI056299-08, R01 AI085669, P01 AI056299, P01 AI039671-16, P01 AI039671-17, P01 AI073748-03, R01 AI085669-01A1, P30 AI060354, P01 AI073748, R01 AI085669-02, P01 AI073748-02, P01 AI073748-01A1, P01 AI039671, P01 AI056299-06A1] Funding Source: Medline
  2. NINDS NIH HHS [R01 NS045937-04, R01 NS045937-07, R01 NS045937-02, R01 NS045937-01, R01 NS045937-05, R01 NS045937-08, R01 NS045937, R01 NS045937-09, R01 NS045937-03, R01 NS045937-06] Funding Source: Medline

Ask authors/readers for more resources

T cell immunoglobulin-3 (Tim-3) has been identified as a marker of differentiated interferon-gamma-producing CD4(+) T helper type 1 and CD8(+) T cytotoxic type 1 cells. The interaction of Tim-3 with its ligand, galectin-9 (Gal-9), induces cell death, and in vivo blockade of this interaction results in exacerbated autoimmunity and abrogation of tolerance in experimental models, establishing Tim-3 as a negative regulatory molecule. Recent studies have uncovered additional mechanisms by which Tim-3 negatively regulates T cell responses, such as promoting the development of CD8+ T cell exhaustion and inducing expansion of myeloid-derived suppressor cells. In contrast to this inhibitory effect on T cells, Tim-3-Gal-9 interaction promotes macrophage clearance of intracellular pathogens. Here, we focus on the emerging role for Tim-3 in tumor and antimicrobial immunity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available